Cathy Eng, Tae Won Kim, Johanna Bendell, Guillem Argilés, Niall C Tebbutt, Maria Di Bartolomeo, Alfredo Falcone, Marwan Fakih, Mark Kozloff, Neil H Segal, et al: Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology 06/2019; 20:849-861
Y. Kanjanapan, D. Day, L. Wang, H. Al-Sawaihey, E. Abbas, A. Namini, L. L. Siu, A.R. Hansen, A.R. Abdul Razak, A. Spreafico, N.B. Leighl, A.M. Joshua, M.O. Butler, D. Hogg, M. Chappell, L. Soultani, K. Chow, S. Boujos, P.L. Bedard. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.Cancer. 2019 Apr 15;125(8):1341-1349. Doi:10.1002/cncr.31999. Epub 2019 Feb 15.
F.J. Ha and L. Spain, A. Dowling, E.M. Kwan, C. Pezaro, D. Day, P.L. Chia, Ben Tran, David Pook, Andrew J. Weickhardt. Timing of Brain Metastases Development in Metastatic Renal Cell Cancer patients treated with Targeted Therapies and Survival Outcomes: an Australian Multicentre Study. Asia Pac J Clin Oncol. 2019 Jan 30. Doi: 10.1111/ajco.13109. [Epub ahead of print]
D. Day, C. Guo, Y. Kanjanapan, B. Tran, A. Spreafico, A.M. Joshua, L. Wang, A.R. Abdul Razak, N.B. Leighl, A.R. Hansen, M.O. Butler, L.L. Siu, J. Desai, P.L. Bedard. Development and Validation of the Princess Margaret immune oncology prognostic index (PM-IPI) for patients treated in immune oncology early phase trials.Submitted to JNCI Cancer Spectrum.
D. Day, A. Prawira, A. Spreafico, J. Waldron, M. Giuliani, I. Weinreb, J. Kim, J. Cho, A. Hope, A. Bayley, J. Ringash, S.V. Bratman, R. Jang, B. O’Sullivan, L.L. Siu, A.R. Hansen. Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.Submitted to Oral Oncology.
Lawrence, Mitchell G; Obinata, Daisuke; Sandhu, Shahneen; Selth, Luke A; Wong, Stephen Q; Porter, Laura H; Lister, Natalie; Pook, David; Pezaro, Carmel J; Goode, David L. Patient-derived models of abiraterone-and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy. European Urology.
Gulley, James L; Borre, Michael; Vogelzang, Nicholas J; Ng, Siobhan; Agarwal, Neeraj; Parker, Chris C; Pook.David W; Rathenborg, Per; Flaig, Thomas W; Carles, Joan. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2019.
Davis, Ian D; Martin, Andrew J; Stockler, Martin R; Begbie, Stephen; Chi, Kim N; Chowdhury, Simon; Coskinas, Xanthi; Frydenberg, Mark; Hague, Wendy E; Horvath, Lisa G; Pook, David W. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. The New England Journal of Medicine, 2019.
Porter, Laura H; Lawrence, Mitchell G; Wang, Hong; Clark, Ashlee K; Bakshi, Andrew; Obinata, Daisuke; Goode, David; Papargiris, Melissa; Clouston, David; Ryan, Andrew; Pook, David W. Establishing a cryopreservation protocol for patient‐derived xenografts of prostate cancer. The Prostate, 2019.
Kwan EM, Fettke H, Docanto MM, To SQ, Bukczynska P, Mant A, Pook David.W, Ng N, Graham LK, Mangiola S, Segelov S, Mahon K, Davis ID, Parente P, Pezaro C, Todenhofer T, Horvath LG, Azad AA. Prognostic utility of a whole blood androgen receptor-based gene signature in metastatic castration-resistant prostate cancer. Eur Urol Focus 2019. In Press. PMID 31103601
Kwan EM, Semira MC, Bergin ART, Muttiah C, Beck S, Anton A, Campbell D, Wong S, Rosenthal M, Gibbs P, Tran B. Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre study. Intern Med J. In Press. PMID 30779277
Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis P, Boyle F, Friedlander M. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. Br J Cancer 2019 Feb;120(3):279-285. PMID 30655615
Fettke H, Kwan EM, Azad AA. Cell-free DNA in cancer: current insights. Cell Oncol (Dordr) 2019;42(1):13-28. PMID 30367445
Ha FJ, Spain L, Dowling A, Kwan EM, Pezaro C, Day D, Chia PL, Tran B, Pook. D W, Weickhardt AJ. Timing of Brain Metastases Development in Metastatic Renal Cell Cancer patients treated with Targeted Therapies and Survival Outcomes: an Australian Multicentre Study. Asia Pac J Clin Oncol 2019. In Press. PMID 30701671
O. Kondrashova, G.Y. Ho, G. Au-Yeung, L. Leas, T. Boughtwood, K. Alsop, G. Zapparoli, A. Dobrovic, Y.A Ko, A.L. Hsu, C.J. Love, S. Lunke, M.J. Wakefield, O. McNally, M. Quinn, S. Ananda, D. Neesham, A. Hamilton, M. Grossi, A. Freimund, Y. Kanjanapan, D. Rischin, N. Traficante, D. Bowtell, C.L. Scott, M. Christie, G.R. Taylor, L. Mileshkin, P.M. Waring. The ALLOCATE study: Clinical utility of real-time targeted molecular profiling in the clinical management of ovarian cancer. JCO Precision Medicine, May 2019
Gerstl B, Sullivan E, Vallejo M, Koch J, Johnson M, Wand H, Webber K, Ives A, Anazodo A, Reproductive outcomes following treatment for a gynecological cancer diagnosis: a systematic review, J Cancer Surviv 13(2) (2019) 269-281
U. Hafeez, S. Menon, B. Nguyen, C. Lum, G. Gaughran, G. pranavan, L. Cher,
A. Nowak, H. Gan, S. Parakh. Young adults diagnosed with high grade gliomas: patterns of care, outcomes, and impact on employment. Accepted for publication July 2019. Journal of clinical Neurosciences.
Wang Y, Logan S, Stern K, Wakefield CE, Cohn RJ, Agresta F, Jayasinghe Y, Deans R, Segelov E, McLachlan RI, Gerstl B. Supportive oncofertility care, psychological health and reproductive concerns: a qualitative study. Supportive Care in Cancer. 2019 Jun:1-9.
Athauda A, Segelov. E, Khan Z, Chau I. 2018. Integrative molecular analysis of colorectal cancer and gastric cancer: what have we learnt? Cancer Treatment Reviews. Cancer Treatment Reviews. 1 Feb 2019, 73, p. 31-40
D. Day, S. Frentzas, C. A. Naidu, E. Segelov and M. Green. Current Utility and Future Applications of ctDNA in Colorectal Cancer , IntechOpen, DOI: 10.5772/intechopen.82316.
Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC? So Y, Frentzas S, Segelov, E. Hepatobiliary Surgery and Nutrition 2019 Aug 5
Wang Y; Logan S; Stern K; Wakefield C; Cohn R; Agresta F; Jayasinghe Y; Deans R; Segelov E; McLachlan R; Gerstl B; Sullivan E; Ledger W; Anazodo A. Supportive Oncofertility Care, Psychological Health and Reproductive Concerns: A Qualitative Study; Supportive Care in Cancer Jun 2019
Kwan E, Fettke H, Docanto M, To S, Bukczynska P, Mant M, Pook D, Ng N, Graham L-J, Mangiola S, Segelov E, Mahon K, Davis I, Parente P, Pezaro C, Todenhofer T, Horvath L, Azad A. Prognostic utility of an androgen receptor splice variant-based gene signature in metastatic castration-resistant prostate cancer. European Urology Focus May 15th 2019.
Symonds EL, Pedersen SK, Murray D, Byrne SE, Hollington P, Rabbitt P, Jones FS, Segelov E; Lazarus TS, LaPointe L, Young G. Circulating epigenetic biomarkers for sensitive detection of recurrent colorectal cancer. Submitted May 2019
Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE) [Journal] Woodward, N, De Boer, R.H., Redfern, A, White. M, Young, J, Truman, M, Beith, J.
Clinical Breast Cancer, 2019, Feb 27.
Cheasley D, Wakefield M, Ryland G, Allen P, Alsop K, Amarasinghe K, Ananda S, Anglesio M, Boehm M, Bowtell D, Chenevix-Trench G, Chiew Y, Christie M, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fereday S, Fox S, Gilks B, Gourley C, Hacker N, Hadley A, Hendley J, Ho G, Hughes S, Hunstman D, Hunter S, Jobling T, Kalli K, Kaufmann S, Kennedy C, Koebel M, Lepage C, Jason Li, Lupat R, McAlpine J, Pyman J, Rowley S, Salazar C, Samimi G, Saunders H, Semple T, Sharpe A, Torres M, Traficante N, Xing C, Zethoven M, Antill Y, Scott C, Campbell A, Gorringe K The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communication; 2019: doi: 10.1038/s41467-019-11862-x
Kondrashova O, Ho G, Au-Yeung G, Leas G, Boughtwood T, Alsop K, Zapparoli G, Dobrovic A, Ko Y, Hsu A, Love C, Lunke S, Wakefield M, McNally O, Quinn M, Ananda S, Neesham D, Hamilton A, Freimund A, Kanjanapan Y, Rischin D, Traficante N, Australian Ovarian Cancer Study, Bowtell D, Scott C, Christie M, Taylor G, Mileshkin L, Waring P The ALLOCATE study: Clinical utility of real-time targeted molecular profiling in the clinical management of ovarian cancer. JCO Precision Medicine; 2019: doi: 10.1200/PO.19.00019
Fettke H, Kwan EM, Yu J, Wang A, Montesinos C, Wong C, Gong X, Zheng T, Du P, Jia S, Mant A, Parente P, Pezaro C, Azad AA. Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients, Poster Presentation, AACR, 2019. Georgia, USA
Kwan EM, To SQ, Fettke HC, Mant A, Docanto MM, Bukczynska P, Mant A, Pook D, Ng N, Graham LK, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Horvath L, Azad AA. Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer, Poster Presentation, ASCO GU, 2019. San Francisco, USA.
Klein O, Kee D, Markman B, Chang Lee R, Michael M, Mileshkin L.R, Scott C.L, Linklater R, Menon S, Tebbutt N.C, Palmer J, Behren A, Cebon J.S. A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendrocrine, and gynaecological maligancies. Journal of Clinical Oncology 2019 37:15.
Balasubramanian A, Pick A, Kumar B, Prodanovic Z, Joshi P, Alamageer M. Treatment outcomes in malignant pleural mesothelioma: A Single center experience of systemic therapies and biomarkers. Journal of Clinical Oncology 2019 37:15.
Sweeny C, Martin A.J, Zielinkski R.R, Thomson A, Hsiang Tan T, Kaur Sandhu S, Reaume M.N, Pook D.W, Parnis F, North S.A McDermott S, McCaffrey J, Marx G.M, Lawrence N.J, Horvath L, Frydenberg M, Chowdhury S, Chi K.N, Stockler M.R, David I.D. Overall Survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. Journal of Clinical Oncology 37, 2019.
Symonds E, Pedersen S, Murray D, Byrne S, Hollington P, Rabbitt P, Jones F, Segelov. E, Lazarus T, Lapointe L, Young G. Performance comparison of the methylated BCAT1/IKZF1 ctDNA test (COLVERA) with the CEA assay for detection of recurrent colorectal cancer. Journal of Clinical Oncology 37 (15) Suppl; 3589 -3589.
Michael, M, Segelov, E. Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial. Journal Clinical Oncology 37 (15).
Kwan E, To S, Fettke H, Docanto M, Bukczynska P, Mant M, Waltham M, Pook D, Ng N, Graham L-J, Segelov E, Mahon K, Davis I, Parente P, Pezaro C, Horvath L, Azad A. Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC). Accepted for ASCO GU, Feb 2019, San Francisco
Millar J, Zheng H, Collopy B, Segelov E. The Development of an Australian National Standard Set of Clinical Indicators for Cancer Care to Monitor and Improve Care for Cancer Patients. Victorian Integrated Cancer Service Conference 2019.
Bucki T, Srivastava R, Wagner I, Segelov E, Sherwell S. Determining the feasibility and impact upon patients and clinicians on the use of a comprehensive geriatric assessment in a Geriatric Oncology clinic, Victorian Integrated Cancer Service Conference 2019